Scientists Discover Molecule That Can Fight Drug-Resistant Bacteria

Drug resistance has become a hot topic over the last couple of years, and it’s bound to stay that way thanks to a rise in monkeypox and polio cases across the US. This pesky (and sometimes deadly) phenomenon occurs when bacteria, fungi, and other germs become impervious to medication, or even capable of destroying the medication once it’s entered the body. One such bacteria, called Gram-negative bacteria, is responsible for a range of health complications including urinary tract infections (UTIs), lung infections, gastroenteritis, and meningitis.

Gram-negative bacteria owes its resilience to a tough outer cell wall that prevents antibiotics and other treatments from permeating its walls. It also contains a number of efflux pumps, a mechanism by which the bacteria can flush unwanted molecules out of the cell. Together, the cell wall and efflux pumps often render antibiotics ineffective, making uncomfortable and life-threatening health issues difficult to treat. But fabimycin, a newly synthesized compound, appears to permeate Gram-negative bacteria’s defenses enough to let medical treatments do their job.

Fabimycin works by targeting an enzyme called FabI, which is integral to the success of Gram-negative bacteria’s defense mechanisms. While FabI inhibitors have been used to treat staph infections (Staphylococcus aureus), scientists haven’t been able to synthesize one capable of bypassing Gram-negative bacteria’s cell walls—until now. According to new research published in ACS Central Science, a team of chemists and molecular biologists at the University of Illinois at Urbana-Champaign, the Broad Institute of MIT and Harvard, and the Walter Reed Army Institute of Research successfully created fabimycin while working to treat a slew of drug-resistant diseases.

So far, tests have shown that fabimycin is an effective tool in treating over 200 isolated Gram-negative bacterial diseases, including E. coli, a rare case of pneumonia called Klebsiella pneumoniae, and a lung and blood pathogen called Acinetobacter baumannii. Lab-simulated treatments, however, are only as effective as their real-world counterparts. In mice, fabimycin not only helped permeate Gram-negative bacteria but also reduced the concentration of those bacteria to the animals’ pre-infection levels.

The discovery of this powerful compound gives the researchers hope that antibiotics might someday be altered to more effectively target drug-resistant diseases. “Fabimycin has translational promise, and its discovery provides additional evidence that antibiotics can be systematically modified to accumulate in Gram-negative bacteria and kill these problematic pathogens,” the team said.

Continue reading

Pentagon May Dump $10 Billion JEDI Program Over Microsoft, Amazon Fight

The government is so tired of fighting with Amazon over the $10 billion JEDI cloud contract that went to Microsoft, it'd rather just quit than move forward with litigation.

Nvidia May Reissue RTX 3060, Other Ampere GPUs to Fight Crypto Mining

Rumors suggest Nvidia will reintroduce a new version of the RTX 3060 designed to thwart cryptocurrency mining more effectively. Other GPUs may be refreshed in the same fashion.

Remote-Control Firefighting Tank, Other Projects Receive Millions in 5G Grants

The Australian government announced late last year it would be providing organizations with up to $2 million AUD each in grants for 5G projects. Now it has revealed the winners.

Intel Does Not Launch Different SSD Configurations Under the Same SKU

Intel has responded to our request for information on its SSD configurations. The company promises it does not swap hardware components post-launch in any situation and has never done so.